Pages that link to "Q34061131"
Jump to navigation
Jump to search
The following pages link to Antinuclear antibody profiles in relation to specific disease manifestations of systemic lupus erythematosus (Q34061131):
Displaying 16 items.
- Myocarditis in systemic lupus erythematosus (Q34980901) (← links)
- Evidence of autoantibodies to cell membrane associated DNA (cultured lymphocytes): a new specific marker for rapid identification of systemic lupus erythematosus (Q35547566) (← links)
- Pathogenic autoantibodies in lupus nephritis (Q36054822) (← links)
- Rheumatic disease among Oklahoma tribal populations: a cross-sectional study (Q36310765) (← links)
- (5R)-5-hydroxytriptolide ameliorates lupus nephritis in MRL/lpr mice by preventing infiltration of immune cells. (Q38720673) (← links)
- Pro-inflammatory S100 proteins are associated with glomerulonephritis and anti-dsDNA antibodies in systemic lupus erythematosus (Q39608198) (← links)
- Anti-Ro(SSA) and anti-La(SSB) antibodies in autoimmune rheumatic diseases (Q40559200) (← links)
- Cardiac tamponade and pericardial disorders in connective tissue diseases: case report and literature review (Q40746214) (← links)
- Differential microRNA profile and post-transcriptional regulation exist in systemic lupus erythematosus patients with distinct autoantibody specificities (Q47603082) (← links)
- Serological markers in Arabs with lupus nephritis (Q48024795) (← links)
- A contemporary case series of lupus myocarditis (Q51318041) (← links)
- Unique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosus. (Q52659257) (← links)
- Prevalence of 13 autoantibodies and of the 16/6 and related pathogenic idiotypes in 465 patients with systemic lupus erythematosus and their relationship with disease activity (Q73523744) (← links)
- The prognosis and outcome of patients referred to an outpatient clinic for rheumatic diseases characterized by the presence of antinuclear antibodies (ANA) (Q74636791) (← links)
- Relationship between clinical factors and neuropsychiatric manifestations in systemic lupus erythematosus (Q81462541) (← links)
- Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE (Q83006345) (← links)